Липосомы – метаболически активные транспортные системы лекарственных средств: классификация, составные компоненты, способы изготовления и стабилизации. Часть 1 (обзор)

Введение. В данном обзоре рассмотрены вопросы современной классификации липосом, методов их изготовления, стабилизации и роли составных компонентов, визуализации, фармакокинетики. В первой части обсуждены первые три вышеупомянутых аспекта.

Текст. Липосомы являются не только перспективными наноконтейнерами для адресной доставки лекарственных средств, но и метаболически активными комплексами с широким спектром активности. Липидные компоненты липосом могут оказать выраженное действие на органы и ткани-мишени. Продукты метаболизма основных компонентов липосом обладают собственной биологической активностью, зависящей от их сочетания и дозировки. Все вышесказанное свидетельствует о перспективности использования липосом не только в качестве носителей ЛС, но и в качестве самостоятельных эффекторов, способных оказать значительное влияние на метаболизм человека при различных заболеваниях. Проведено сравнение преимуществ и ограничений методов получения липосом, рассмотрены особенности изготовления стелс-липосом. Отдельно обсуждены вопросы стабилизации липосом.

Заключение. Обсужденная в обзоре информация может быть полезна при разработке лекарственных средств в форме липосом.

1. Pattni B. S., Chupin V. V., Torchilin V. P. New developments in liposomal drug delivery. Chemical Reviews. 2015;115(19):10938–10966. DOI: 10.1021/acs.chemrev.5b00046.

2. Liu P., Chen G., Zhang J. A review of liposomes as a drug delivery system: Current status of approved products, regulatory environments, and future perspectives. Molecules. 2022;27(4):1372. DOI: 10.3390/molecules27041372.

3. Бурдаев Н. И., Николаева Л. Л., Косенко В. В., Шпрах З. С., Бунятян Н. Д. Липосомы как носители лекарственных средств: классификация, методы получения и применение. Ведомости Научного центра экспертизы средств медицинского применения. Регуляторные исследования и экспертиза лекарственных средств. 2023;13(2–1):316–332. DOI: 10.30895/1991-2919-2023-508.

4. Jesorka A., Orwar O. Liposomes: technologies and analytical applications. Annual Review of Analytical Chemistry. 2008;1:801–832. DOI: 10.1146/annurev.anchem.1.031207.112747.

5. Tokudome Y., Saito Y., Sato F., Kikuchi M., Hinokitani T., Goto K. Preparation and characterization of ceramide-based liposomes with high fusion activity and high membrane fluidity. Colloids and Surfaces B: Biointerfaces. 2009;73(1):92–96. DOI: 10.1016/j.colsurfb.2009.05.002.

6. Spector A. A., Yorek M. A. Membrane lipid composition and cellular function. Journal of Lipid Research. 1985;26(9):1015–1035.

7. Kiss Z. Determination of phospholipase D-mediated hydrolysis of phosphatidylethanolamine. Lipids. 1991;26:321–323. DOI: 10.1007/BF02537144.

8. Richmond G. S., Smith T. K. Phospholipases A₁. International Journal of Molecular Sciences. 2011;12(1):588–612. DOI: 10.3390/ijms12010588.

9. Zhao Y., Hasse S., Bourgoin S. G. Phosphatidylserine-specific phospholipase A1: A friend or the devil in disguise. Progress in Lipid Research. 2021;83:101112. DOI: 10.1016/j.plipres.2021.101112.

10. Lands W. E. Metabolism of glycerolipids: II. The enzymatic acylation of lysolecithin. Journal of Biological chemistry. 1960;235(8):2233–2237.

11. Ho C.-L., Lin Y.-L., Li S.-F. Three toxins with phospholipase activity isolated from the yellow-legged hornet (Vespa verutina) venom. Toxicon. 1999;37(7):1015–1024. DOI: 10.1016/s0041-0101(98)00229-3.

12. Thomson F. J., Clark M. A. Purification of a phosphatidic-acid-hydrolysing phospholipase A 2 from rat brain. Biochemical Journal. 1995;306(1):305–309. DOI: 10.1042/bj3060305.

13. Ren J., Lin J., Yu L., Yan M. Lysophosphatidylcholine: Potential Target for the Treatment of Chronic Pain. International Journal of Molecular Sciences. 2022;23(15):8274. DOI: 10.3390/ijms23158274.

14. Plemel J. R., Michaels N. J., Weishaupt N., Caprariello A. V., Keough M. B., Rogers J. A., Yukseloglu A., Lim J., Patel V. V., Rawji K. S., Jensen S. K., Teo W., Heyne B., Whitehead S. N., Stys P. K, Yong V. W. Mechanisms of lysophosphatidylcholine-induced demyelination: A primary lipid disrupting myelinopathy. Glia. 2018;66(2):327–347. DOI: 10.1002/glia.23245.

15. Drzazga A., Sowińska A., Koziołkiewicz M. Lysophosphatidylcholine and lysophosphatidylinosiol--novel promissing signaling molecules and their possible therapeutic activity. Acta poloniae pharmaceutica. 2014;71(6):887–899.

16. Endo Y., Kanno T., Nakajima T., Ikeda K., Taketomi Y., Yokoyama S., Sasamoto S., Asou H. K., Miyako K., Hasegawa Y., Kawashima Y., Ohara O., Murakami M., Nakayama T. 1-Oleoyl-lysophosphatidylethanolamine stimulates RORγt activity in TH17 cells. Science Immunology. 2023;8(86):eadd4346. DOI: 10.1126/sciimmunol.add4346.

17. Yamamoto Y., Sakurai T., Chen Z., Inoue N., Chiba H., Hui S.-P. Lysophosphatidylethanolamine Affects Lipid Accumulation and Metabolism in a Human Liver-Derived Cell Line. Nutrients. 2022;14(3):579. DOI: 10.3390/nu14030579.

18. Park S.-J., Im D.-S. 2-Arachidonyl-lysophosphatidylethanolamine Induces Anti-Inflammatory Effects on Macrophages and in Carrageenan-Induced Paw Edema. International Journal of Molecular Sciences. 2021;22(9):4865. DOI: 10.3390/ijms22094865.

19. Bill C. A., Vines C. M. Phospholipase C. Calcium signaling. 2020;1131:215–242. DOI: 10.1007/978-3-030-12457-1_9.

20. Takaoka R., Kurosaki H., Nakao H., Ikeda K., Nakano M. Formation of asymmetric vesicles via phospholipase D-mediated transphosphatidylation. Biochimica et Biophysica Acta (BBA)-Biomembranes. 2018;1860(2):245–249. DOI: 10.1016/j.bbamem.2017.10.011.

21. Hou H.-J., Gong J.-S., Dong Y.-X., Qin J., Li H., Li H., Lu Z.-M., Zhang X.-M., Xu Z.-H., Shi J.-S. Phospholipase D engineering for improving the biocatalytic synthesis of phosphatidylserine. Bioprocess and Biosystems Engineering. 2019;42(7):1185–1194. DOI: 10.1007/s00449-019-02116-7.

22. Arora H., Culler M. D., Decker E. A. Production of a High-Phosphatidylserine Lecithin That Synergistically Inhibits Lipid Oxidation with α-Tocopherol in Oil-in-Water Emulsions. Foods. 2022;11(7):1014. DOI: 10.3390/foods11071014.

23. Guertin D. A., Sabatini D. M. An expanding role for mTOR in cancer. Trends in Molecular Medicine. 2005;11(8):353–361. DOI: 10.1016/j.molmed.2005.06.007.

24. Литвинко Н. М. Межфазный катализ липолитических реакций в биоорганической химии: особенности и практическое применение. Известия Национальной академии наук Беларуси. Серия химических наук. 2015;(4):109–121.

25. Aguilar A., Saba J. D. Truth and consequences of sphingosine-1-phosphate lyase. Advances in Biological Regulation. 2012;52(1):17–30. DOI: 10.1016/j.advenzreg.2011.09.015.

26. Iqbal J., Walsh M. T., Hammad S. M., Hussain M. M. Sphingolipids and Lipoproteins in Health and Metabolic Disorders. Trends in Endocrinology & Metabolism. 2017;28(7):506–518. DOI: 10.1016/j.tem.2017.03.005.

27. Gulbins A., Grassmé H., Hoehn R., Wilker B., Soddemann M., Kohnen M., Edwards M. J., Kornhuber J., Gulbins E. Regulation of Neuronal Stem Cell Proliferation in the Hippocampus by Endothelial Ceramide. Cellular Physiology and Biochemistry. 2016;39(2):790–801. DOI: 10.1159/000447789.

28. Cruciani-Guglielmacci C., López M., Campana M., Le Stunff H. Brain Ceramide Metabolism in the Control of Energy Balance. Frontiers in Physiology. 2017;8:787. DOI: 10.3389/fphys.2017.00787.

29. Jana A., Hogan E. L., Pahan K. Ceramide and neurodegeneration: susceptibility of neurons and oligodendrocytes to cell damage and death. Journal of the Neurological Sciences. 2009;278(1–2):5–15. DOI: 10.1016/j.jns.2008.12.010.

30. Jiang M., Chavarria T. E., Yuan B., Lodish H. F., Huang N.-J. Phosphocholine accumulation and PHOSPHO1 depletion promote adipose tissue thermogenesis. Proceedings of the National Academy of Sciences. 2020;117(26):15055–15065. DOI: 10.1073/pnas.1916550117.

31. Grabitzki J., Lochnit G. Immunomodulation by phosphocholine–biosynthesis, structures and immunological implications of parasitic PC-epitopes. Molecular Immunology. 2009;47(2–3):149–163. DOI: 10.1016/j.molimm.2009.09.035.

32. Clark S. E., Weiser J. N. Microbial modulation of host immunity with the small molecule phosphorylcholine. Infection and Immunity. 2013;81(2):392–401. DOI: 10.1128/IAI.01168-12.

33. Cartier A., Hla T. Sphingosine 1-phosphate: Lipid signaling in pathology and therapy. Science. 2019;366(6463):eaar5551. DOI: 10.1126/science.aar5551.

34. Hodun K., Chabowski A., Baranowski M. Sphingosine-1-phosphate in acute exercise and training. Scandinavian Journal of Medicine & Science in Sports. 2021;31(5):945–955. DOI: 10.1111/sms.13907.

35. Blanc M., Hsieh W. Y., Robertson K. A., Kropp K. A., Forster T., Shui G., Lacaze P., Watterson S., Griffiths S. J., Spann N. J., Meljon A., Talbot S., Krishnan K., Covey D. F., Wenk M. R., Craigon M., Ruzsics Z., Haas J., Angulo A., Griffiths W. J., Glass C. K., Wang Y., Ghazal P. The transcription factor STAT-1 couples macrophage synthesis of 25-hydroxycholesterol to the interferon antiviral response. Immunity. 2013;38(1):106–118. DOI: 10.1016/j.immuni.2012.11.004.

36. Zang R., Case J. B., Yutuc E., Ma X., Shen S., Gomez Castro M. F., Liua Z., Zeng Q., Zhao H., Son J., Rothlauf P. W., Kreutzberger A. J. B., Hou G., Zhang H., Bosem S., Wang X., Vahey M. D., Mani K., Griffiths W. J., Kirchhausen T., Fremont D. H., Guo H., Diwane A., Wang Y., Diamond M. S., Whelan S. P. J., Ding S. Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion. Proceedings of the National Academy of Sciences. 2020;117(50):32105–32113. DOI: 10.1073/pnas.2012197117.

37. Griffiths W. J., Wang Y. Cholesterol metabolism: from lipidomics to immunology. Journal of Lipid Research. 2022;63(2):100165. DOI: 10.1016/j.jlr.2021.100165.

38. Chambers K. F., Day P. E., Aboufarrag H. T., Kroon P. A. Polyphenol effects on cholesterol metabolism via bile acid biosynthesis, CYP7A1: A Review. Nutrients. 2019;11(11):2588. DOI: 10.3390/nu11112588.

39. Zhang J., Zhu Y., Wang X., Wang J. 25-hydroxycholesterol: an integrator of antiviral ability and signaling. Frontiers in Immunology. 2023;14:1268104. DOI: 10.3389/fimmu.2023.1268104.

40. Kakiyama G., Minowa K., Rodriguez-Agudo D., Martin R., Takei H., Mitamura K., Ikegawa S., Suzuki M., Nittono H., Fuchs M., Heuman D. M., Zhou H., Pandak W. M. Coffee modulates insulin-hepatocyte nuclear factor-4α-Cyp7b1 pathway and reduces oxysterol-driven liver toxicity in a nonalcoholic fatty liver disease mouse model. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2022;323(5):G488–G500. DOI: 10.1152/ajpgi.00179.2022.

41. Chiang J. Y. L., Ferrell J. M. Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis. Liver Research. 2020;4(2):47–63. DOI: 10.1016/j.livres.2020.05.001.

42. Noguchi N., Saito Y., Urano Y. Diverse functions of 24(S)-hydroxycholesterol in the brain. Biochemical and Biophysical Research Communications. 2014;446(3):692–696. DOI: 10.1016/j.bbrc.2014.02.010.

43. Bikle D., Christakos S. New aspects of vitamin D metabolism and action – addressing the skin as source and target. Nature Reviews Endocrinology. 2020;16(4):234-252. DOI: 10.1038/s41574-019-0312-5.

44. Титов В. Н. Атеросклероз как патология полиеновых жирных кислот. Биологические основы теории атерогенеза. Москва: Клиника XXI века; 2002. 495 с.

45. Wang B., Wu L., Chen J., Dong L., Chen C., Wen Z., Hu J., Fleming I., Wang D. W. Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets. Signal Transduction and Targeted Therapy. 2021;6(1):94. DOI: 10.1038/s41392-020-00443-w.

46. Biernacki M., Skrzydlewska E. Metabolism of endocannabinoids. Postępy Higieny i Medycyny Doświadczalnej. 2016;70(0):830–843. DOI: 10.5604/17322693.1213898.

47. Serhan C. N., Levy B. D. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. Journal of Clinical Investigation. 2018;128(7):2657–2669. DOI: 10.1172/JCI97943.

48. Hu J., Lin S., Zheng B., Cheung P. C. K. Short-chain fatty acids in control of energy metabolism. Critical Reviews in Food Science and Nutrition. 2018;58(8):1243–1249. DOI: 10.1080/10408398.2016.1245650.

49. De Carvalho C. C. R., Caramujo M. J. The Various roles of fatty acids. Molecules. 2018;23(10):2583. DOI: 10.3390/molecules23102583.

50. Bangham A. D., Standish M. M., Weissmann G. The action of steroids and streptolysin S on the permeability of phospholipid structures to cations. Journal of Molecular Biology. 1965;13(1):253–259. DOI: 10.1016/S0022-2836(65)80094-8.

51. Brunner J., Skrabal P., Hauser H. Single bilayer vesicles prepared without sonication physico-chemical properties. Biochimica et Biophysica Acta (BBA) – Biomembranes. 1976;455(2):322–331. DOI: 10.1016/0005-2736(76)90308-4.

52. Batzri S., Korn E. D. Single bilayer liposomes prepared without sonication. Biochimica et Biophysica Acta (BBA) – Biomembranes. 1973;298(4):1015–1019. DOI: 10.1016/0005-2736(73)90408-2.

53. Szoka F., Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proceedings of the National Academy of Sciences. 1978;75(9):4194–4198. DOI: 10.1073/pnas.75.9.4194.

54. New R. R. Liposomes. Oxford: IRL at Oxford University Press; 1990. 301 p.

55. Kim S., Martin G. M. Preparation of cell-size unilamellar liposomes with high captured volume and defined size distribution. Biochimica et Biophysica Acta (BBA) – Biomembranes. 1981;646(1):1–9. DOI: 10.1016/0005-2736(81)90264-9.

56. Karn P.-R., Cho W., Park H. J., Park J. S., Hwang S. J. Characterization and stability studies of a novel liposomal cyclosporin A prepared using the supercritical fluid method: comparison with the modified conventional Bangham method. International Journal of Nanomedicine. 2013:365–377. DOI: 10.2147/IJN.S39025.

57. Nicolosi D., Scalia M., Nicolosi V. M., Pignatello R. Encapsulation in fusogenic liposomes broadens the spectrum of action of vancomycin against Gram-negative bacteria. International Journal of Antimicrobial Agents. 2010;35(6):553–558. DOI: 10.1016/j.ijantimicag.2010.01.015.

58. Lehmann J., Agel M. R., Engelhardt K. H., Pinnapireddy S. R., Agel S., Duse L., Preis E., Wojcik M., Bakowsky U. Improvement of pulmonary photodynamic therapy: Nebulisation of curcumin-loaded tetraether liposomes. Pharmaceutics. 2021;13(8):1243. DOI: 10.3390/pharmaceutics13081243.

59. Phapal S. M., Sunthar P. Influence of micro-mixing on the size of liposomes self-assembled from miscible liquid phases. Chemistry and Physics of Lipids. 2013;172:20–30. DOI: 10.1016/j.chemphyslip.2013.04.006.

60. Mozafari M. R., Reed C. J., Rostron C. Cytotoxicity evaluation of anionic nanoliposomes and nanolipoplexes prepared by the heating method without employing volatile solvents and detergents. Pharmazie. 2007;62(3):205–209.

61. Saliba A.-E., Vonkova I., Deghou S., Ceschia S., Tischer C., Kugler K. G., Bork P., Ellenberg J., Gavin A.-C. A protocol for the systematic and quantitative measurement of protein-lipid interactions using the liposome-microarray-based assay. Nature Protocols. 2016; 11(6):1021–1038. DOI: 10.1038/nprot.2016.059.

62. Devrim B., Kara A., Vural İ., Bozkır A. Lysozyme-loaded lipid-polymer hybrid nanoparticles: preparation, characterization and colloidal stability evaluation. Drug Development and Industrial Pharmacy. 2016;42(11):1865–1876. DOI: 10.1080/03639045.2016.1180392.

63. Anabousi S., Laue M., Lehr C.-M., Bakowsky U., Ehrhardt C. Assessing transferrin modification of liposomes by atomic force microscopy and transmission electron microscopy. European Journal of Pharmaceutics and Biopharmaceutics. 2005;60(2):295–303. DOI: 10.1016/j.ejpb.2004.12.009.

64. Sivadasan D., Sultan M. H., Madkhali O. A., Alsabei S. H., Alessa A. A. Stealth liposomes (PEGylated) containing an anticancer drug camptothecin: In vitro characterization and in vivo pharmacokinetic and tissue distribution study. Molecules. 2022;27(3):1086. DOI: 10.3390/molecules27031086.

65. Shetti P., Jalalpure S. S., Patil A. S., Kaur K. Apigenin-loaded stealth liposomes: Development and pharmacokinetic studies for enhanced plasma retention of drug in cancer therapy. Topics in Catalysis. 2024;67(1):46–58. DOI: 10.1007/s11244-023-01818-3.

66. Gheibi Hayat S. M., Jaafari M. R., Hatamipour M., Penson P. E., Sahebkar A. Liposome circulation time is prolonged by CD47 coating. Protein & Peptide Letters. 2020;27(10):1029–1037. DOI: 10.2174/0929866527666200413100120.

67. Wang Z., Zhao Y., Jiang Y., Lv W., Wu L., Wang B., Lv L., Xu Q., Xin H. Enhanced anti-ischemic stroke of ZL006 by T7-conjugated PEGylated liposomes drug delivery system. Scientific Reports. 2015;5(1):12651. DOI: 10.1038/srep12651.

68. Sylvester B., Porfire A., Muntean D.-M., Vlase L., Lupuţ L., Licarete E., Sesarman A., Costel Alupei M., Banciu M., Achim M., Tomuţă I. Optimization of prednisolone-loaded long-circulating liposomes via application of Quality by Design (QbD) approach. Journal of Liposome Research. 2018;28(1):49–61. DOI: 10.1080/08982104.2016.1254242.

69. Maherani B., Arab-Tehrany E., Mozafari M. R., Gaiani C., Linder M. Liposomes: A Review of Manufacturing Techniques and Targeting Strategies. Current Nanoscience. 2011;7(3):436–52. DOI: 10.2174/157341311795542453.

70. Crowe L. M., Crowe J. H., Rudolph A., Womersley C., Appel L. Preservation of freeze-dried liposomes by trehalose. Archives of Biochemistry and Biophysics. 1985;242(1):240–247. DOI: 10.1016/0003-9861(85)90498-9.

71. Stark B., Pabst G., Prassl R. Long-term stability of sterically stabilized liposomes by freezing and freeze-drying: Effects of cryoprotectants on structure. European Journal of Pharmaceutical Sciences. 2010;41(3–4):546–555. DOI: 10.1016/j.ejps.2010.08.010.

72. Stadnichenko O. V., Krasnopolsky Y. M., Yarnykh T. G. The study of liophilization parameters in the liposomal irinotecan development. News of Pharmacy. 2017;4(92):45–49.

73. Franzé S., Selmin F., Samaritani E., Minghetti P., Cilurzo F. Lyophilization of liposomal formulations: still necessary, still challenging. Pharmaceutics. 2018;10(3):139. DOI: 10.3390/pharmaceutics10030139.

74. Filipe V., Hawe A., Jiskoot W. Critical evaluation of nanoparticle tracking analysis (NTA) by nanosight for the measurement of nanoparticles and protein aggregates. Pharmaceutical Research. 2010;27:796–810. DOI: 10.1007/s11095-010-0073-2.

75. Pedreira de Almeida A. C., Matos Alves Pinto L., Piovesan Alves G., Nunes de Morais Ribeiro L., Andrade Santana M. H., Saia Cereda C. M., Fernandes Fraceto L., de Paula E. Liposomal-based lidocaine formulation for the improvement of infiltrative buccal anaesthesia. Journal of Liposome Research. 2019;29(1),66–72. DOI: 10.1080/08982104.2018.1483947.

76. Kent B., Garvey C. J., Cookson D., Bryant G. The inverse hexagonal – inverse ribbon – lamellar gel phase transition sequence in low hydration DOPC:DOPE phospholipid mixtures. Chemistry and Physics of Lipids. 2009;157(1):56–60. DOI: 10.1016/j.chemphyslip.2008.10.003.

77. Guida V. Thermodynamics and kinetics of vesicles formation processes. Advances in Colloid and Interface Science. 2010;161(1–2):77–88. DOI: 10.1016/j.cis.2009.11.004.

78. Cohen J. A. Electrophoretic characterization of liposomes. Methods in Enzymology. 2003;367:148–176. DOI: 10.1016/S0076-6879(03)67011-4.

79. Heurtault B., Saulnier P., Pech B., Proust J.-E., Benoit J.-P. Physico-chemical stability of colloidal lipid particles. Biomaterials. 2003;24(23):4283–4300. DOI: 10.1016/S0142-9612(03)00331-4.

80. Стадниченко А. В., Краснопольский Ю. М., Ярных Т. Г. Оптимизация параметров дзета-потенциала при создании липосом с иринотеканом. Фармация Казахстана. 2017;6:7–10.

81. Стадниченко А. В., Краснопольский Ю. М., Ярных Т. Г. Изучение факторов, влияющих на стабильность липосом с цитостатиками при регидратации. Рецепт. 2017;20(2):146–152.

82. Гулякин И. Д., Николаева Л. Л., Дмитриева М. В., Оборотова Н. А., Орлова О. Л., Полозкова А. П. Разработка лиофилизированной липосомальной лекарственной формы производного индолокарбазола – ЛХС-1208. Фармацевтическое дело и технология лекарств. 2020;(5):66–78.

83. Vélez M. A., Perotti M. C., Hynes E. R., Gennaro A. M. Effect of lyophilization on food grade liposomes loaded with conjugated linoleic acid. Journal of Food Engineering. 2019;240:199–206. DOI: 10.1016/j.jfoodeng.2018.07.033.

84. Yadav A. V, Murthy M. S., Shete A. S., Sakhare S. Stability aspects of liposomes. Indian Journal of Pharmaceutical Education and Research. 2011;45(4):402–413.

85. D’souza A. A., Shegokar R. Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications. Expert Opinion on Drug Delivery. 2016;13(9):1257–1275. DOI: 10.1080/17425247.2016.1182485.